Phaseline

Companies › Beijing Yongtai Ruike Biotechnology Company

Beijing Yongtai Ruike Biotechnology Company: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CAR-T-19 cell injection
anti-CD19 chimeric antigen receptor T cell therapy
CD19Phase 2Relapsed B-cell Acute Lymphoblastic LeukemiaApr 2027
RC19D2 cell injection
anti-CD19 chimeric antigen receptor (CAR-T) cell therapy
CD19Phase 1Recurrent Diffuse Large B-Cell LymphomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06047197RC19D2 cell injectionPhase 1Recurrent Diffuse Large B-Cell LymphomaOncologyDec 2026
NCT06179524CAR-T-19 cell injectionPhase 2Relapsed B-cell Acute Lymphoblastic LeukemiaOncologyApr 2027

Targets

CD19 (2)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Shanghai Ming Ju Biotechnology iCell Gene Therapeutics ImmunityBio

Companies built like this

Shanghai Ming Ju Biotechnology Juventas Cell Therapy PersonGen BioTherapeutics (Suzhou) Hebei Senlang Biotechnology Autolus

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.